Strategic Priorities Laid Out for 2024
Building on a year of progress. Following a banner year for InMed in 2023, including significant advancement and expansion of its rare cannabinoids-focused pharmaceuticals development programs and a breakout year for BayMedica’s commercial operations, the company has laid out its strategic priorities for 2024. We will be hosting a fireside chat with CEO and President Eric A. Adams on January 25, 2024, at 1:00 pm ET. Registration link is available in our full report. Advancing a potentially novel approach to treating Alzheimer’s. In October 2023, InMed took a significant step forward in its INM-900 series program targeting neurodegenerative diseases after confirming that it has made its final selection of a lead Alzheimer’s disease drug candidate. Based on initial preclinical data from in vitro and in vivo studies, the identified cannabinoid analog (INM-901) appears not only to be potentially effective in reducing beta-amyloid plaques (the focus of the current FDA-approved disease-modifying drugs for treating Alzheimer’s), but also seems to have the unique potential to provide neuroprotective effects and enhanced neuronal function. InMed has initiated six-month preclinical studies in behavioral models to further evaluate the potential impact of INM-901 on Alzheimer’s disease with preparations underway for the subsequent phase of advanced preclinical studies. These will encompass drug distribution, metabolism, and active pharmaceutical ingredient (API) and drug product formulation/manufacturing. Preparing an IND filing for new AMD program. Knowledge gleaned from InMed’s preclinical work in its glaucoma program (INM-088) has facilitated the advancement of preclinical work using a proprietary cannabinoid analog (INM-089) for the treatment of age-related macular degeneration disease (AMD), the most common cause of vision loss and potential blindness in people 50 years of age and older. Early preclinical results from an in vivo AMD disease model have demonstrated that INM-089 may have the potential to preserve retinal function, proactively protect retinal cells, and enhance the thickness of the outer nuclear layer of the retina where photoreceptors are situated. InMed is currently engaged in API and drug product formulation work as part of its effort to advance preclinical evaluations of INM-089. InMed intends to initiate an Investigational New Drug (IND) enabling studies in mid-2024, with submission of an IND application to the FDA anticipated in 1H25. This submission will potentially enable InMed to commence human clinical trials of the drug candidate in 2025.
Water Tower Research is built on the foundation of democratizing information flow. We bridge the growing information gap between companies and investors through our investor engagement strategies and open-access research platform.
Our research analysts are Wall Street veterans with the experience and knowledge to work with companies and investors in tandem. We provide access to the information and content that anchors the due diligence process for both professional money managers and individual investors. We leverage traditional research distribution channels and the best of modern digital strategies and tactics to amplify this information flow globally to engage all categories of investors and stakeholders.
Information flow is the foundation for creating investor awareness, knowledge, and engagement. Our mission is to help companies and investors have the tools they need and achieve their goals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.